🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma

RecruitingPhase 1, Phase 2Ages 18 Years - 75 YearsAllRuijin Hospital
NCT07885319 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This Phase 1b/2, open-label, multicenter, single-arm study evaluates the safety and efficacy of ivonescimab in combination with pemetrexed and platinum-based chemotherapy as first-line treatment for advanced malignant pleural mesothelioma. Phase 1b evaluates the candidate recommended Phase 2 dose (RP2D), followed by Phase 2 evaluation at the confirmed RP2D.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age 18 to 75 years. 2. Histologically confirmed advanced or metastatic malignant pleural mesothelioma not amenable to surgery. 3. No prior systemic anticancer therapy for advanced disease. 4. ECOG PS 0-1. 5. At least one measurable lesion according to modified RECIST (mRECIST). 6. Adequate organ function for study treatment. 7. Patients with asymptomatic or stable brain metastases are eligible. 8. Able to understand the study, provide written informed consent, and comply with study procedures. Exclusion Criteria: 1. Active autoimmune disease requiring systemic treatment or other contraindications to immunotherapy. 2. Uncontrolled hypertension, significant bleeding risk, or other contraindications to antiangiogenic therapy. 3. Active interstitial lung disease or noninfectious pneumonitis. 4. Active infection requiring systemic treatment. 5. Other active malignancies requiring anticancer treatment. 6. Severe uncontrolled medical conditions that may interfere with study treatment. 7. Pregnant or breastfeeding women.
💊

What it tests

  • Ivonescimab Combined With Chemotherapy
📍

Where

3 sites
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
Shanghai Chest Hospital
Shanghai, China
West China Hospital of Sichuan University
Chengdu, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy